{"transactions":[{"id":957935,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":70813,"kind":"person","name":"Einhorn Andrew J.","position":1,"cik":"0001560685","reported_name":"Einhorn Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-29T16:16:56.000Z","date":"2025-12-23","kind":"grant","planned":false,"acquired":true,"shares":12000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On December 23, 2025, the Reporting Person was granted 12,000 Restricted Stock Units (the \"RSUs\") of the issuer, as compensation for the Reporting Person's service as a member of the issuer's board of directors, pursuant to the issuer's 2023 Equity Incentive Plan, as amended and restated effective as of April 16, 2025 (the \"Plan\"). The RSUs will vest on January 1, 2027. Each RSU represents a contingent right to receive one share of issuer's Common Stock, par value $0.0001 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 23, 2025, the Reporting Person was granted 12,000 Restricted Stock Units (the \"RSUs\") of the issuer, as compensation for the Reporting Person's service as a member of the issuer's board of directors, pursuant to the issuer's 2023 Equity Incentive Plan, as amended and restated effective as of April 16, 2025 (the \"Plan\"). The RSUs will vest on January 1, 2027. Each RSU represents a contingent right to receive one share of issuer's Common Stock, par value $0.0001 per share."}],"balance_after":12000,"source":{"system":"sec-edgar","filing":"0001753926-25-001991","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1560685/000175392625001991/ownership.xml","form_type":"4"}},{"id":2424958,"issuer":{"id":108806,"kind":"organization","name":"RVL Pharmaceuticals plc","symbol":"RVLP"},"owners":[{"id":70813,"kind":"person","name":"Einhorn Andrew J.","position":1,"cik":"0001560685","reported_name":"Einhorn Andrew J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2022-01-26T16:31:55.000Z","date":"2022-01-24","kind":"tax_withholding","acquired":false,"shares":9607,"price":1.13,"value":10855.91,"ownership":{"direct":true},"balance_after":141473,"source":{"system":"sec-edgar","filing":"0001104659-22-007844","document":"tm223506-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1560685/000110465922007844/tm223506-4_4seq1.xml","form_type":"4"}},{"id":2521072,"issuer":{"id":108806,"kind":"organization","name":"RVL Pharmaceuticals plc","symbol":"RVLP"},"owners":[{"id":70813,"kind":"person","name":"Einhorn Andrew J.","position":1,"cik":"0001560685","reported_name":"Einhorn Andrew J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Share Option (Right to Buy)","published_at":"2021-11-08T16:06:20.000Z","date":"2021-11-04","kind":"grant","acquired":true,"shares":249814,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the ordinary shares underlying the award on the first anniversary of the grant and as to the remaining 75% of the shares in thirty-six (36) equal monthly installments thereafter."}],"balance_after":249814,"derivative":{"exercise_price":1.8,"expiration_date":"2031-11-04","underlying":"Ordinary Shares","underlying_shares":249814},"source":{"system":"sec-edgar","filing":"0001104659-21-135637","document":"tm2132232-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1560685/000110465921135637/tm2132232-2_4seq1.xml","form_type":"4"}},{"id":2702521,"issuer":{"id":108806,"kind":"organization","name":"RVL Pharmaceuticals plc","symbol":"RVLP"},"owners":[{"id":70813,"kind":"person","name":"Einhorn Andrew J.","position":1,"cik":"0001560685","reported_name":"Einhorn Andrew J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2021-05-20T16:06:04.000Z","date":"2021-05-18","kind":"tax_withholding","acquired":false,"shares":6467,"price":3.12,"value":20177.04,"ownership":{"direct":true},"balance_after":151080,"source":{"system":"sec-edgar","filing":"0001104659-21-069879","document":"tm2117061-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1560685/000110465921069879/tm2117061-1_4seq1.xml","form_type":"4"}},{"id":2894831,"issuer":{"id":108806,"kind":"organization","name":"RVL Pharmaceuticals plc","symbol":"RVLP"},"owners":[{"id":70813,"kind":"person","name":"Einhorn Andrew J.","position":1,"cik":"0001560685","reported_name":"Einhorn Andrew J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2021-01-26T19:02:30.000Z","date":"2021-01-24","kind":"tax_withholding","acquired":false,"shares":9668,"price":4.46,"value":43119.28,"ownership":{"direct":true},"balance_after":157547,"source":{"system":"sec-edgar","filing":"0001104659-21-007785","document":"tm214203-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1560685/000110465921007785/tm214203-3_4seq1.xml","form_type":"4"}},{"id":3140412,"issuer":{"id":108806,"kind":"organization","name":"RVL Pharmaceuticals plc","symbol":"RVLP"},"owners":[{"id":70813,"kind":"person","name":"Einhorn Andrew J.","position":1,"cik":"0001560685","reported_name":"Einhorn Andrew J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance-Based Restricted Stock Units","published_at":"2020-05-20T21:48:59.000Z","date":"2020-05-18","kind":"grant","acquired":true,"shares":71550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The performance-based restricted stock units represent a contingent right to receive, upon vesting, a varying number of the registrant's ordinary shares based on certain pre-determined thresholds for the closing price of registrant's ordinary shares on the Nasdaq Global Select Market.  The performance-based restricted stock units vest on the third anniversary of the date of grant and, upon vesting, will convert into 0%, 50%, 100% or 150% of the target number of ordinary shares listed in Column 7 of Table II."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The performance-based restricted stock units represent a contingent right to receive, upon vesting, a varying number of the registrant's ordinary shares based on certain pre-determined thresholds for the closing price of registrant's ordinary shares on the Nasdaq Global Select Market.  The performance-based restricted stock units vest on the third anniversary of the date of grant and, upon vesting, will convert into 0%, 50%, 100% or 150% of the target number of ordinary shares listed in Column 7 of Table II."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The performance-based restricted stock units represent a contingent right to receive, upon vesting, a varying number of the registrant's ordinary shares based on certain pre-determined thresholds for the closing price of registrant's ordinary shares on the Nasdaq Global Select Market.  The performance-based restricted stock units vest on the third anniversary of the date of grant and, upon vesting, will convert into 0%, 50%, 100% or 150% of the target number of ordinary shares listed in Column 7 of Table II."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The performance-based restricted stock units represent a contingent right to receive, upon vesting, a varying number of the registrant's ordinary shares based on certain pre-determined thresholds for the closing price of registrant's ordinary shares on the Nasdaq Global Select Market.  The performance-based restricted stock units vest on the third anniversary of the date of grant and, upon vesting, will convert into 0%, 50%, 100% or 150% of the target number of ordinary shares listed in Column 7 of Table II."}],"balance_after":71550,"derivative":{"underlying":"Ordinary Shares","underlying_shares":71550},"source":{"system":"sec-edgar","filing":"0001104659-20-064440","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1560685/000110465920064440/a4.xml","form_type":"4"}},{"id":3140411,"issuer":{"id":108806,"kind":"organization","name":"RVL Pharmaceuticals plc","symbol":"RVLP"},"owners":[{"id":70813,"kind":"person","name":"Einhorn Andrew J.","position":1,"cik":"0001560685","reported_name":"Einhorn Andrew J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2020-05-20T21:48:59.000Z","date":"2020-05-18","kind":"grant","acquired":true,"shares":71550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock units."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units."}],"balance_after":167215,"source":{"system":"sec-edgar","filing":"0001104659-20-064440","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1560685/000110465920064440/a4.xml","form_type":"4"}},{"id":3297611,"issuer":{"id":108806,"kind":"organization","name":"RVL Pharmaceuticals plc","symbol":"RVLP"},"owners":[{"id":70813,"kind":"person","name":"Einhorn Andrew J.","position":1,"cik":"0001560685","reported_name":"Einhorn Andrew J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2020-01-30T17:38:50.000Z","date":"2020-01-28","kind":"tax_withholding","acquired":false,"shares":9184,"price":7,"value":64288.0,"ownership":{"direct":true},"balance_after":95665,"source":{"system":"sec-edgar","filing":"0001104659-20-008837","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1560685/000110465920008837/a4.xml","form_type":"4"}},{"id":3685137,"issuer":{"id":108806,"kind":"organization","name":"RVL Pharmaceuticals plc","symbol":"RVLP"},"owners":[{"id":70813,"kind":"person","name":"Einhorn Andrew J.","position":1,"cik":"0001560685","reported_name":"Einhorn Andrew J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2019-01-28T17:49:35.000Z","date":"2019-01-24","kind":"grant","acquired":true,"shares":104849,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock units."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units."}],"balance_after":104849,"source":{"system":"sec-edgar","filing":"0001104659-19-003723","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1560685/000110465919003723/a4.xml","form_type":"4"}},{"id":4388646,"issuer":{"id":7939,"kind":"organization","name":"PDS Biotechnology Corp","symbol":"PDSB"},"owners":[{"id":70813,"kind":"person","name":"Einhorn Andrew J.","position":1,"cik":"0001560685","reported_name":"Einhorn Andrew J.","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Warrants (right To Purchase)","published_at":"2017-03-13T17:47:14.000Z","date":"2017-03-01","kind":"other","acquired":false,"shares":1567,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":2.39,"exercise_date":"2012-09-09","expiration_date":"2017-09-09","underlying":"Common Stock","underlying_shares":1567},"source":{"system":"sec-edgar","filing":"0001127602-17-011377","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1472091/000112760217011377/form4.xml","form_type":"4"}},{"id":4388645,"issuer":{"id":7939,"kind":"organization","name":"PDS Biotechnology Corp","symbol":"PDSB"},"owners":[{"id":70813,"kind":"person","name":"Einhorn Andrew J.","position":1,"cik":"0001560685","reported_name":"Einhorn Andrew J.","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-03-13T17:47:14.000Z","date":"2017-03-01","kind":"other","acquired":true,"shares":1567,"price":2.39,"value":3745.13,"ownership":{"direct":true},"balance_after":43223,"source":{"system":"sec-edgar","filing":"0001127602-17-011377","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1472091/000112760217011377/form4.xml","form_type":"4"}}]}